Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01805024 · ClinicalTrials.gov registry record · Phase 1

Congenital Muscular Dystrophy Ascending Multiple Dose Cohort Study Analyzing Pharmacokinetics at Three Dose Levels In Children and Adolescents With Assessment of Safety and Tolerability of Omigapil (CALLISTO)

A Phase 1 study, sponsored by Santhera Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target

NCT01805024: Completed Phase 1 study, sponsored by Santhera Pharmaceuticals.

NCT01805024 is a Phase 1 study that has completed, run by Santhera Pharmaceuticals. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01805024, a Phase 1 study, has completed, sponsored by Santhera Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target

Study Summary

The purpose of the study is to establish the pharmacokinetic profile of omigapil in paediatric and adolescent patients with CMD and to evaluate the safety and tolerability of omigapil. Funding source - FDA OOPD

Interventions

  • DRUG Omigapil

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2014-12
Est. Completion 2018-01-29
Phase Phase 1
Santhera Pharmaceuticals

7 total trials

What the finished NCT01805024 record still lists

NCT01805024 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).

The record links to 0 conditions, and to 1 intervention - of which Omigapil is the first listed.

NCT01805024 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01805024 about?

NCT01805024 is a clinical study titled "Congenital Muscular Dystrophy Ascending Multiple Dose Cohort Study Analyzing Pharmacokinetics at Three Dose Levels In Children and Adolescents With Assessment of Safety and Tolerability of Omigapil (CALLISTO)". The purpose of the study is to establish the pharmacokinetic profile of omigapil in paediatric and adolescent patients with CMD and to evaluate the safety and tolerability of omigapil. Funding source - FDA OOPD

What is the current status of trial NCT01805024?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2014-12. Estimated completion is 2018-01-29.

What interventions are being tested in trial NCT01805024?

The interventions under investigation include: Omigapil (DRUG).

Who is sponsoring clinical trial NCT01805024?

This trial is sponsored by Santhera Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01805024's enrollment target sits among peer trials

20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01805024, the US trial registry maintained by the National Library of Medicine. NCT01805024 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.